隆華新材(301149.SZ):公司2024年上半年聚醚系列產品銷售量達30.47萬噸
格隆匯9月10日丨隆華新材(301149.SZ)在投資者互動平台表示,公司2023年度聚醚系列產品銷售量達54.16萬噸,公司2024年上半年聚醚系列產品銷售量達30.47萬噸,為國內聚醚行業龍頭企業,深受國內外用户的認可及支持。公司聚醚產品具有高固含量、低粘度、遇水不凝膠、超低VOC、高白度等優勢,產品品類眾多,不同產品性能不盡相同,可滿足客户的個性化需求,用途廣泛,各產品利潤率有所差異。同時,利潤率水平與宏觀環境、行業情況、市場供求關係、企業自身情況等多因素相關。公司產品的定價模式為緊盯主要原材料成本,綜合考慮市場供求情況等因素制定銷售價格。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.